Investigational Drug Information for Enobosarm
✉ Email this page to a colleague
What is the development status for investigational drug Enobosarm?
Enobosarm is an investigational drug.
There have been 11 clinical trials for Enobosarm.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 12th 2021.
The most common disease conditions in clinical trials are Urinary Incontinence, Stress, Urinary Incontinence, and Enuresis. The leading clinical trial sponsors are GTx, Veru Inc., and City of Hope Medical Center.
There are thirty-seven US patents protecting this investigational drug and six hundred and fifty-nine international patents.
Summary for Enobosarm
| US Patents | 37 |
| International Patents | 659 |
| US Patent Applications | 171 |
| WIPO Patent Applications | 61 |
| Japanese Patent Applications | 10 |
| Clinical Trial Progress | Phase 3 (2021-10-12) |
| Vendors | 37 |
Recent Clinical Trials for Enobosarm
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer | Veru Inc. | Phase 2 |
| Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer | Veru Inc. | Phase 3 |
| Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence | GTx | Phase 2 |
Clinical Trial Summary for Enobosarm
Top disease conditions for Enobosarm
Top clinical trial sponsors for Enobosarm
US Patents for Enobosarm
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Enobosarm | ⤷ Sign Up | SARMs and method of use thereof | University of Tennessee Research Foundation (Knoxville, TN) | ⤷ Sign Up |
| Enobosarm | ⤷ Sign Up | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN) GTX, INC. (Memphis, TN) | ⤷ Sign Up |
| Enobosarm | ⤷ Sign Up | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | GTX, INC. (Memphis, TN) | ⤷ Sign Up |
| Enobosarm | ⤷ Sign Up | Selective androgen receptor modulator and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN) | ⤷ Sign Up |
| Enobosarm | ⤷ Sign Up | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | GTX, INC. (Memphis, TN) UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN) | ⤷ Sign Up |
| Enobosarm | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Enobosarm
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Enobosarm | Argentina | AR061980 | 2026-07-12 | ⤷ Sign Up |
| Enobosarm | Argentina | AR062536 | 2026-07-12 | ⤷ Sign Up |
| Enobosarm | Austria | AT344233 | 2020-08-24 | ⤷ Sign Up |
| Enobosarm | Austria | AT423092 | 2020-08-24 | ⤷ Sign Up |
| Enobosarm | Austria | AT430125 | 2020-08-24 | ⤷ Sign Up |
| Enobosarm | Austria | AT526959 | 2020-08-24 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
